Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Souhil Lebdai, Mathieu Gigoux, Ricardo Alvim, Alexander Somma, Karan Nagar, Abdel Rahmene Azzouzi, Olivier Cussenot, Taha Merghoub, Jedd D. Wolchok, Avigdor Scherz, Kwanghee Kim & Jonathan Coleman. (2019) Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. OncoImmunology 8:6.
Read now
Read now
Emeric Limagne, Corentin Richard, Marion Thibaudin, Jean-David Fumet, Caroline Truntzer, Aurélie Lagrange, Laure Favier, Bruno Coudert & François Ghiringhelli. (2019) Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. OncoImmunology 8:4.
Read now
Read now
Articles from other publishers (43)
Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu & Harriet M. Kluger. (2023) A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 22:1.
Crossref
Crossref
Ruiyang Ren, Chenyi Xiong, Runyu Ma, Yixuan Wang, Tianyang Yue, Jiayun Yu & Bin Shao. (2023) The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers. MedComm 4:4.
Crossref
Crossref
Maria del Mar Maldonado, Jeffrey Schlom & Duane H. Hamilton. (2023) Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment. Cancer Immunology, Immunotherapy.
Crossref
Crossref
Quan Chen, Bingkun Chen, Chunhua Wang, Li Hu, Qiongwen Wu, Yanyang Zhu & Qiuyu Zhang. (2023) Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma. Frontiers in Immunology 14.
Crossref
Crossref
Jennifer Cao, Lyndah Chow & Steven Dow. (2023) Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment. Frontiers in Oncology 13.
Crossref
Crossref
Shivani Yadav, Astik Priya, Diksha R. Borade & Reena Agrawal-Rajput. (2022) Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance. Immunologic Research 71:2, pages 130-152.
Crossref
Crossref
Fadhl Alshaebi, Mohammed Safi, Yousif A. Algabri, Mahmoud Al-Azab, Abdullah Aldanakh, Mohammed Alradhi, Alariqi Reem & Caiqing Zhang. (2023) Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. Frontiers in Oncology 13.
Crossref
Crossref
Lyndsey S. Crump, Kelsey T. Kines, Jennifer K. Richer & Traci R. Lyons. (2022) Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. American Journal of Physiology-Cell Physiology 323:5, pages C1475-C1495.
Crossref
Crossref
Bingzhe LV, Yunpeng Wang, Dongjiang Ma, Wei Cheng, Jie Liu, Tao Yong, Hao Chen & Chen Wang. (2022) Immunotherapy: Reshape the Tumor Immune Microenvironment. Frontiers in Immunology 13.
Crossref
Crossref
Zibing Wang, Yuqing Liu, Ling Peng, Brian Till, Yuwei Liao, Shumin Yuan, Xiang Yan, Lin Chen, Qiang Fu & Zhihai Qin. (2022) Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses. Oncogene 41:10, pages 1434-1444.
Crossref
Crossref
Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia M Yegodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jérôme Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G T Morris, Pierre Saintigny & Moshe Elkabets. (2022) MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. Journal for ImmunoTherapy of Cancer 10:3, pages e003917.
Crossref
Crossref
Ali N. Chamseddine, Tarek Assi, Olivier Mir & Salem Chouaib. (2022) Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Pharmacology & Therapeutics 231, pages 107986.
Crossref
Crossref
Manzoor A. Mir, Shazia Sofi & Hina Qayoom. 2022. Combinational Therapy in Triple Negative Breast Cancer. Combinational Therapy in Triple Negative Breast Cancer
121
148
.
Davood Bashash, Zahra Zandi, Bahareh Kashani, Atieh Pourbagheri‐Sigaroodi, Sina Salari & Seyed H. Ghaffari. (2021) Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology 237:1, pages 346-372.
Crossref
Crossref
Xueyan Li, Jiahui Zhong, Xue Deng, Xuan Guo, Yantong Lu, Juze Lin, Xuhui Huang & Changjun Wang. (2021) Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Y. Dirix, Radka Obermannova, Jonathan E. Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua Sabari, Sonya Chapman, Wei Zhang, Boris Calderon & Daniel A. Peterson. (2021) A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Investigational New Drugs 39:5, pages 1284-1297.
Crossref
Crossref
Jingshan Cai, Yudan Cui, Jun Yang & Shengjun Wang. (2021) Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:1, pages 188564.
Crossref
Crossref
Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang & Xia Zhao. (2021) Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Huaqing Mo, Yanrong Hao, Yanru Lv, Zenan Chen, Jingyi Shen, Shu Zhou & MengJie Yin. (2021) Overexpression of macrophage-colony stimulating factor-1 receptor as a prognostic factor for survival in cancer. Medicine 100:12, pages e25218.
Crossref
Crossref
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, Svetomir N. Markovic, Paola Nisticò & Alberto Signore. (2020) Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Karen A. Autio, Christopher A. Klebanoff, David Schaer, John Sae Wook Kauh, Susan F. Slovin, Matthew Adamow, Victoria S. Blinder, Manisha Brahmachary, Michelle Carlsen, Elizabeth Comen, Daniel C. Danila, Thompson N. Doman, Jeremy C. Durack, Josef J. Fox, Jill S. Gluskin, David M. Hoffman, Suhyun Kang, Praneet Kang, Jonathan Landa, Philomena F. McAndrew, Shanu Modi, Michael J. Morris, Ruslan Novosiadly, Dana E. Rathkopf, Rachel Sanford, Sonya C. Chapman, Courtney M. Tate, Danni Yu, Phillip Wong & Heather L. McArthur. (2020) Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clinical Cancer Research 26:21, pages 5609-5620.
Crossref
Crossref
Reem Saleh & Eyad Elkord. (2020) Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology 65, pages 13-27.
Crossref
Crossref
Daniel Shae, Jessalyn J. Baljon, Mohamed Wehbe, Kyle W. Becker, Taylor L. Sheehy & John Tanner Wilson. (2019) At the bench: Engineering the next generation of cancer vaccines. Journal of Leukocyte Biology 108:4, pages 1435-1453.
Crossref
Crossref
Yufei Wang, Anna Jia, Yujing Bi, Yuexin Wang, Qiuli Yang, Yejin Cao, Yan Li & Guangwei Liu. (2020) Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Cancers 12:9, pages 2626.
Crossref
Crossref
Eline Janssen, Beatriz Subtil, Fàtima de la Jara Ortiz, Henk M. W. Verheul & Daniele V. F. Tauriello. (2020) Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers 12:7, pages 1875.
Crossref
Crossref
Asif A. Dar, Rushikesh S. Patil, Trupti N. Pradhan, Devendra A. Chaukar, Anil K. D’Cruz & Shubhada V. Chiplunkar. (2020) Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma. Cancer Immunology, Immunotherapy 69:6, pages 1071-1086.
Crossref
Crossref
Aohan Hou, Kaiyu Hou, Qiubo Huang, Yujie Lei & Wanling Chen. (2020) Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Frontiers in Immunology 11.
Crossref
Crossref
Shazia K. Nakhoda & Anthony J. Olszanski. (2020) Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceutical Medicine 34:2, pages 83-91.
Crossref
Crossref
Malek Kreidieh, Deborah Mukherji, Sally Temraz & Ali Shamseddine. (2020) Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International 2020, pages 1-24.
Crossref
Crossref
Francesca Di Modugno, Cristina Colosi, Paola Trono, Giuseppe Antonacci, Giancarlo Ruocco & Paola Nisticò. (2019) 3D models in the new era of immune oncology: focus on T cells, CAF and ECM. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Olivier Demaria, Stéphanie Cornen, Marc Daëron, Yannis Morel, Ruslan Medzhitov & Eric Vivier. (2019) Harnessing innate immunity in cancer therapy. Nature 574:7776, pages 45-56.
Crossref
Crossref
Kristen B. Long, Arthur I. Collier & Gregory L. Beatty. (2019) Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance. Molecular Immunology 110, pages 3-12.
Crossref
Crossref
Huizhong Xiong, Stephanie Mittman, Ryan Rodriguez, Marina Moskalenko, Patricia Pacheco-Sanchez, Yagai Yang, Dorothee Nickles & Rafael Cubas. (2019) Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Research 79:7, pages 1493-1506.
Crossref
Crossref
Chunwan Lu, Dafeng Yang, John D. Klement, Il Kyu Oh, Natasha M. Savage, Jennifer L. Waller, Aaron H. Colby, Mark W. Grinstaff, Nicholas H. Oberlies, Cedric J. Pearce, Zhiliang Xie, Samuel K. Kulp, Christopher C. Coss, Mitch A. Phelps, Thomas Albers, Iryna O. Lebedyeva & Kebin Liu. (2019) SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunology Research 7:3, pages 414-427.
Crossref
Crossref
David J. Zahavi & Louis M. Weiner. (2019) Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. International Journal of Molecular Sciences 20:1, pages 158.
Crossref
Crossref
Kevin Van der Jeught, Han-Chen Xu, Yu-Jing Li, Xiong-Bin Lu & Guang Ji. (2018) Drug resistance and new therapies in colorectal cancer. World Journal of Gastroenterology 24:34, pages 3834-3848.
Crossref
Crossref
Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal & Viktor Umansky. (2018) Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Frontiers in Immunology 9.
Crossref
Crossref
Michael J. OvermanMarc S. ErnstoffMichael A. Morse. (2018) Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. American Society of Clinical Oncology Educational Book:38, pages 239-247.
Crossref
Crossref
Natalie J. Neubert, Martina Schmittnaegel, Natacha Bordry, Sina NassiriNoémie WaldChristophe Martignier, Laure Tillé, Krisztian HomicskoWilliam Damsky, Hélène Maby-El Hajjami, Irina KlamanEsther DanenbergKalliopi Ioannidou, Lana Kandalaft, George Coukos, Sabine Hoves, Carola H. Ries, Silvia A. Fuertes MarracoPeriklis G. FoukasMichele De Palma & Daniel E. Speiser. (2018) T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine 10:436.
Crossref
Crossref
Sabine Hoves, Chia-Huey Ooi, Carsten Wolter, Hadassah Sade, Stefan Bissinger, Martina Schmittnaegel, Oliver Ast, Anna M. Giusti, Katharina Wartha, Valeria Runza, Wei Xu, Yvonne Kienast, Michael A. Cannarile, Hyam Levitsky, Solange Romagnoli, Michele De Palma, Dominik Rüttinger & Carola H. Ries. (2018) Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine 215:3, pages 859-876.
Crossref
Crossref
Paola Trono, Antonella Sistigu, Belinda Palermo, Gennaro Ciliberto & Paola Nisticò. (2017) Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences 1:5, pages 471-486.
Crossref
Crossref
Dung T. Le, Vanessa M. Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur N. Brodsky, Emily Chan, Dustin A. Deming, Luis A. DiazJrJr, Wolf H. Fridman, Richard M. Goldberg, Stanley R. Hamilton, Franck Housseau, Elizabeth M. Jaffee, S. Peter Kang, Smitha S. Krishnamurthi, Christopher H. Lieu, Wells Messersmith, Cynthia L. Sears, Neil H. Segal, Arvin Yang, Rebecca A. Moss, Edward Cha, Jill O'Donnell-Tormey, Nancy Roach, Anjelica Q. Davis, Keavy McAbee, Sharyn Worrall & Al B. Benson. (2017) A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research 5:11, pages 942-949.
Crossref
Crossref
Jonathan Rios-Doria, Jay Harper, Raymond Rothstein, Leslie Wetzel, Jon Chesebrough, Allison Marrero, Cui Chen, Patrick Strout, Kathy Mulgrew, Kelly McGlinchey, Ryan Fleming, Binyam Bezabeh, John Meekin, David Stewart, Maureen Kennedy, Philip Martin, Andrew Buchanan, Nazzareno Dimasi, Emil Michelotti & Robert Hollingsworth. (2017) Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Research 77:10, pages 2686-2698.
Crossref
Crossref